Oditrasertib

DB21526InvestigationalSmall molecule

Oditrasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Oditrasertib is a serine/threonine kinase inhibitor. Oditrasertib is under investigation in clinical... Oditrasertib is under investigation in clinical trial NCT05630547 (A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis).

Mechanism: Pharmacologically active on Receptor-interacting serine/threonine-protein kinase 1
Curator reviewed
Formula / weight: C₁₄H₁₅F₂N₃O₂ · 295.29 g/mol (avg)
Code names: C19061501-F · DN0002489 · DN-2489 · DNL-788 · RA-15804589 · SAR-443820

Resolves to

Compound

UNIII1YQT8HC89CAS2252271-93-3ChEMBLCHEMBL5314474ChEBI759180PubChem135382587

Structure

InChIKeyCSCLQCHKUAMZOY-UHFFFAOYSA-NSMILESCC(C)(C(F)F)C(=O)N1CCOC2=C(C=NC=C2C1)C#N

Targets

Q13546RIPK1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oditrasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account